Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001813 · ClinicalTrials.gov registry record

Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
709
Enrollment target

NCT00001813: Completed study, sponsored by National Cancer Institute (NCI).

NCT00001813 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 709 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001813 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
709 participants
Enrollment target

Study Summary

Four rare genetic diseases, xeroderma pigmentosum (XP), Cockayne syndrome (CS), the XP/CS complex and trichothiodystrophy (TTD) have defective DNA excision repair although only XP has increased cancer susceptibility. We plan to perform careful clinical examination of selected patients with XP, XP/CS, CS, or TTD and follow their clinical course. We will obtain tissue (skin, blood, hair, buccal swabs) for laboratory examination of DNA repair and for genetic analysis. We hope to be able to correlate these laboratory abnormalities with the clinical features to better understand the mechanism of cancer prevention by DNA repair. Patients will be offered counseling and education for cancer control.

Trial Details

FieldValue
Enrollment Target 709 participants
Start Date 1999-05-10

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00001813

The ClinicalTrials.gov registry entry for NCT00001813 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 709 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00001813 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00001813 about?

NCT00001813 is a clinical study titled "Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy". Four rare genetic diseases, xeroderma pigmentosum (XP), Cockayne syndrome (CS), the XP/CS complex and trichothiodystrophy (TTD) have defective DNA excision repair although only XP has increased cancer susceptibility. We plan to perform careful clinical examination of selected patients with XP, XP/CS...

What is the current status of trial NCT00001813?

This trial is currently completed. The enrollment target is 709 participants. The study started on 1999-05-10.

Who is sponsoring clinical trial NCT00001813?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.